Rohto Pharmaceutical Co.,Ltd.

4527

JP3982400008

Pharmaceuticals

Delayed Japan Exchange Other stock markets 08:25:55 2024-05-16 pm EDT			5-day change	1st Jan Change
2,882 ^JPY	-0.29%		-8.46%	+1.30%

Apr. 04	Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	MT
Apr. 04	Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	DJ

Rohto Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2021

February 17, 2021 at 01:00 am EST

Rohto Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2021. For the year, the company expected net sales of JPY 183,000 million, operating income of JPY 218,000 million and profit attributable to owners of parent of JPY 14,000 million or JPY 122.73 per share.

Latest news about Rohto Pharmaceutical Co.,Ltd.

Rohto Pharmaceutical Eyes MGO on Singapore's Eu Yan Sang International for 88 Billion Yen	Apr. 04	MT
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang -- Update	Apr. 04	DJ
Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang	Apr. 04	RE
Rohto Pharmaceutical, Mitsui & Co. to Acquire Singapore-Based Eu Yan Sang	Apr. 04	DJ
Rohto Pharmaceutical Co.,Ltd., Mitsui & Co., Ltd. and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.	Apr. 03	CI
FiNC Technologies Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	Mar. 27	CI
Rohto Pharmaceutical's Profit Climbs 21% in Fiscal Nine Months, Lifts Fiscal-Year Outlook	Feb. 12	MT
Alina Vision Pte Ltd. announced that it has received funding from Fred Hollows Foundation, Rohto Pharmaceutical Co.,Ltd., TVM Capital Healthcare Partners	Jan. 15	CI
Plantex Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd., Dai-ichi Life Holdings, Inc., RealTechJapan LLC.	Nov. 29	CI
Rohto Pharmaceutical Co.,Ltd.(TSE:4527) added to S&P Japan Mid Cap 100	Nov. 29	CI
Japanese Shares Close Marginally Higher Monday Ahead of Biden-Xi Meeting	Nov. 13	MT
Rohto Pharmaceutical’s Attributable Profit Soars 25.8% in Fiscal H1 on Significant Profit Increases Across Categories	Nov. 12	MT
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024	Nov. 10	CI
Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023	Nov. 10	CI
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	Nov. 10	CI
Australis Scientific Pty Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	23-10-24	CI
Butterfly Pea Laboratory Co., Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd. and other investors.	23-10-01	CI
Rohto Pharmaceutical’s Attributable Profit Rises 30% in Fiscal Q1 due to Significant Sales Increase	23-08-25	MT
Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024	23-08-09	CI
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	23-08-09	CI
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending March 31, 2024	23-08-09	CI
Rohto Pharmaceutical's FY23 Profit Rises Nearly 25%	23-05-23	MT
Oishii Plus Co. Ltd. announced that it has received funding from Rohto Pharmaceutical Co.,Ltd.	23-05-17	CI
Rohto Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Second Quarter of Fiscal Year Ending March 31, 2024	23-05-11	CI

Chart Rohto Pharmaceutical Co.,Ltd.

Duration

Period

More charts

Company Profile

ROHTO PHARMACEUTICAL CO., LTD. is a Japan-based company principally engaged in the health and beauty care area. The Company primarily provides eye care-related products, including eye drops and eye lotions; skin care-related products, including dermatological preparations, lip balms, sunscreens and functional cosmetics; oral medication and food-related products, including digestive medicines, Chinese herbal medicines and supplements, as well as extracorporeal test drugs and other products. The Company operates its business in domestic market and overseas markets, including Europe, Asia and America.

Sector

Pharmaceuticals

Calendar

2024-08-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Rohto Pharmaceutical Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,890 JPY

Average target price

3,955 JPY

Spread / Average Target

+36.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROHTO PHARMACEUTICAL CO.,LTD.	+1.35%	4.26B
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals